Micreos offers bacteriophage-based alternative to traditional antibiotics

Dutch biotech company Micreos' endolysin-based product Staphefeckt has shown promise in early case studies as a treatment for skin infections, exciting hopes of a new avenue of treatment in the battle against multi-drug antibiotic resistance.

Dutch biotech company Micreos' endolysin-based product Staphefeckt has shown promise in early case studies as a treatment for skin infections, exciting hopes of a new avenue of treatment in the battle against multi-drug antibiotic resistance.

Presenting the case studies at the EuroSciCon meeting in London, the company said its product Endolysin Staphefekt was able to...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Dermatological

More from Therapeutic Category